Aclarion, Inc. (ACON)
| Market Cap | 10.79M |
| Revenue (ttm) | 58,287 |
| Net Income (ttm) | -2.32M |
| Shares Out | 7.82M |
| EPS (ttm) | -0.30 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 130,960 |
| Open | 1.67 |
| Previous Close | 1.64 |
| Day's Range | 1.35 - 1.76 |
| 52-Week Range | 1.26 - 4.05 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About ACON
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), and a proprietary biomarker to optimize clinical treatments. The first application of Aclarion’s technology addresses the $134.5B U.S. low back and neck pain market. The Company, which has limited sales to date, is addressing this market by initially focusing on improving the outcomes of surgical interventions to treat low back pain. In this initial application, Aclarion technology is intended to assist surgeons in determining the optimal s...
Financial Performance
In 2021, Aclarion's revenue was $60,292, an increase of 23.93% compared to the previous year's $48,652. Losses were -$4.95 million, 6.80% more than in 2020.
Financial StatementsNews
Aclarion IPO Registration Document (S-1)
Aclarion has filed to go public with an IPO on the NASDAQ.